329 related articles for article (PubMed ID: 15958589)
1. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
2. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
3. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Gao N; Kramer L; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2006 Aug; 70(2):645-55. PubMed ID: 16672643
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
5. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection.
Hallaert DY; Spijker R; Jak M; Derks IA; Alves NL; Wensveen FM; de Boer JP; de Jong D; Green SR; van Oers MH; Eldering E
Cell Death Differ; 2007 Nov; 14(11):1958-67. PubMed ID: 17703234
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional modulation of apoptosis regulators by roscovitine and related compounds.
Garrofé-Ochoa X; Cosialls AM; Ribas J; Gil J; Boix J
Apoptosis; 2011 Jul; 16(7):660-70. PubMed ID: 21505869
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
10. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
11. The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis.
Leitch AE; Riley NA; Sheldrake TA; Festa M; Fox S; Duffin R; Haslett C; Rossi AG
Eur J Immunol; 2010 Apr; 40(4):1127-38. PubMed ID: 20127676
[TBL] [Abstract][Full Text] [Related]
12. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
13. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.
Gomez-Bougie P; Bataille R; Amiot M
Eur J Immunol; 2004 Nov; 34(11):3156-64. PubMed ID: 15459900
[TBL] [Abstract][Full Text] [Related]
14. Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
Jorda R; Navrátilová J; Hušková Z; Schütznerová E; Cankař P; Strnad M; Kryštof V
Chem Biol Drug Des; 2014 Oct; 84(4):402-8. PubMed ID: 24803299
[TBL] [Abstract][Full Text] [Related]
15. Seliciclib in malignancies.
Aldoss IT; Tashi T; Ganti AK
Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
[TBL] [Abstract][Full Text] [Related]
16. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
Gómez-Benito M; Marzo I; Anel A; Naval J
Mol Pharmacol; 2005 Jun; 67(6):1991-8. PubMed ID: 15738311
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.
Faber AC; Chiles TC
Cell Cycle; 2007 Dec; 6(23):2982-9. PubMed ID: 18156799
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
[TBL] [Abstract][Full Text] [Related]
20. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
